Tunitas Therapeutics, Inc.

San Francisco, CA 94158

SBIR Award Summary

Total Number of Awards 12
Total Value of Awards $8.34MM
First Award Date 05/01/10
Most Recent Award Date 02/01/15

Key Personnel

Last Name Name Awards Contact
Saxon Andrew Saxon 12
Sigal Nolan Sigal 12

12 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 02/01/15 - 01/31/16

DESCRIPTION (provided by applicant): The overall goal of this phase 2 SBIR proposal is to position our novel biologic GE2 for human clinical trials in allergic disease though the completion of critical preclinical development research activities. GE2, a genetically engineered human fusion protein consisting of portions of the human gamma1 Fc li...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 06/01/14 - 05/31/15

DESCRIPTION (provided by applicant): The overall goal of this phase 2 SBIR proposal is to develop and commercialize a novel biologic for allergen- specific immunotherapy as effective treatment for cat allergy/asthma. Cat allergy is common, with 17% of US population, age 6-59, being skin test positive for cat and 60% of those individuals have sy...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 02/01/14 - 01/31/15

DESCRIPTION (provided by applicant): The overall goal of this phase 2 SBIR proposal is to position our novel biologic GE2 for human clinical trials in allergic disease though the completion of critical preclinical development research activities. GE2, a genetically engineered human fusion protein consisting of portions of the human gamma1 Fc li...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 06/01/13 - 05/31/14

DESCRIPTION (provided by applicant): The overall goal of this phase 2 SBIR proposal is to develop and commercialize a novel biologic for allergen- specific immunotherapy as effective treatment for cat allergy/asthma. Cat allergy is common, with 17% of US population, age 6-59, being skin test positive for cat and 60% of those individuals have sy...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-10-124
Budget: 03/01/13 - 02/28/14

DESCRIPTION (provided by applicant): The overall goal of this Phase 2 STTR is to develop and commercialize a novel approach for allergen specific immunotherapy as a treatment for severe food allergy. Currently treatment to prevent severe food reactions is a major unmet need. There is no effective therapy, the only treatment being strict avoidan...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 02/15/13 - 01/31/14

DESCRIPTION (provided by applicant): The overall goal of this phase 2 SBIR proposal is to position our novel biologic GE2 for human clinical trials in allergic disease though the completion of critical preclinical development research activities. GE2, a genetically engineered human fusion protein consisting of portions of the human gamma1 Fc li...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 06/15/12 - 05/31/13

DESCRIPTION (provided by applicant): The overall goal of this phase 2 SBIR proposal is to develop and commercialize a novel biologic for allergen- specific immunotherapy as effective treatment for cat allergy/asthma. Cat allergy is common, with 17% of US population, age 6-59, being skin test positive for cat and 60% of those individuals have sy...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 04/01/12 - 09/30/12

DESCRIPTION (provided by applicant): The overall goal of this proposal is to develop and commercialize a novel biologic therapy for the treatment of allergic disease and particularly allergic asthma. Specifically, this proposal will provide the critical immunogenicity, mechanistic and biomarker data that will position a novel biologic, GE2, for ...

Phase 2 STTR

Agency: Department of Health & Human Services
Topic: PA-10-124
Budget: 03/15/12 - 02/28/13

DESCRIPTION (provided by applicant): The overall goal of this Phase 2 STTR is to develop and commercialize a novel approach for allergen specific immunotherapy as a treatment for severe food allergy. Currently treatment to prevent severe food reactions is a major unmet need. There is no effective therapy, the only treatment being strict avoidan...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 04/01/11 - 03/31/12

DESCRIPTION (provided by applicant): The overall goal of this proposal is to develop and commercialize a novel biologic therapy for the treatment of allergic disease and particularly allergic asthma. Specifically, this proposal will provide the critical immunogenicity, mechanistic and biomarker data that will position a novel biologic, GE2, for ...

Load More